VINC Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $0.00 and $1.43. With a market capitalization of about $78.51 thousand, Vincerx Pharma, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.41). Key stats such as the average daily volume over the past year has been around 5.08 thousand shares, volume is running light vs its 52-week average. Headquartered in Palo Alto, CA, Vincerx Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Raquel E. Izumi, the company employs approximately 13 people and listed since May 27, 2020. Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S.

VINC has shown weak momentum, losing -1.02% over the past week and -96.09% over the past quarter, though year-to-date performance is down -99.08%. Short-term trend indicators are bullishly aligned (SMA20 -5.26%, SMA50 -81.97%, SMA200 -99.08%). The stock’s 14-day RSI is 24.64 (weak momentum), while the ATR of 0.03 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.72% below its high and over 15.59% above its low. Average 10-day trading volume of 660.00 shares is below the 3-month average of 5.86 thousand, indicating normal recent market interest.

Vincerx Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.48. This means the shares are trading below this model’s fair value.

The latest quarter delivered EPS of -$4.20. The next quarter is forecast at $nan. Next year's EPS is expected at $50.49. Vincerx Pharma, Inc. earnings surprise history is a mixed track record. The quarter that ended March 27, 2025, missed forecasts by 23.53%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -45.24% in March 29, 2024.

Vincerx Pharma, Inc. has 5.23 million shares outstanding. The public float is 4.75 million shares, elevated short interest at 2.72% of float. This equals 137.20 thousand shares. The short ratio is 0.1 days. Institutional investors hold 5.48% of the float. Insiders own 4.11%. Hwang Sooin holds 390.49 thousand shares, THOMAS TOM C has 219.94 thousand shares and Hamdy Ahmed MD has 96.06 thousand shares.